Table 3

The impact of rheumatic diagnosis on neutralising capacity and anti-RBD-IgG levels in patients with AIRD (n=308) compared with controls (n=296)

Rheumatic diagnosis, nNeutralising capacity (%)Anti-RBD-IgG (S/CO)
Median (IQR)Unadjusted
p value
p value
Median (IQR)Unadjusted
p value
p value
Immunocompetent controls, n=29696.5 (93.5–97.1)(ref)(ref)6.7 (6.3–7.1)(ref)(ref)
Rheumatoid arthritis, n=12876.9 (35.6–92.9)<0.0010.8885.1 (0.9–6.4)<0.0010.666
Psoriatic arthritis, n=4595.3 (83.6–96.7)0.1080.5835.9 (3.6–6.9)<0.0010.190
Axial spondyloarthritis, n=2894.5 (84.5–96.8)0.5990.8106.2 (4.2–6.8)0.0010.062
Systemic lupus erythematosus, n=3395.3 (90.3–96.7)0.0010.2156.3 (3.9–7.0)<0.0010.901
Systemic sclerosis, n=1296.5 (93.7–96.7)0.9280.3146.2 (5.2–6.6)0.5270.442
Primary Sjögren's syndrome, n=995.9 (88.6–96.4)0.3350.3736.2 (6.0, 6.7)
Myositis, n=734.8 (7.7–96.2)<0.0010.5710.2 (0, 6.3)<0.0010.477
ANCA-associated vasculitides, n=1711.6 (2.9, 46.1)<0.0010.7580 (0, 0.6)<0.0010.580
Polymyalgia rheumatica/giant cell arteritis, n=1095.3 (86.7, 96.4)0.5860.6595.3 (4.5, 6.5)0.0690.148
IgG4-related disease, n=794.6 (10.9, 95.8)0.0110.5875.5 (0, 6.2)0.0020.636
Autoinflammatory syndromes, n=696.5 (82.8, 97.0)0.5670.5936.5 (5.1, 6.9)0.4910.399
Other AIRD, n=6*91.2 (0, 94.1)<0.0010.2264 (0, 5.3)<0.0010.116
  • P values were estimated by a Wald test as combined p value of the two-part model. Statistically significant results in bold. A hyphen indicates that calculation was not possible within the model.

  • Adjusted multivariable analysis includes the covariates age, sex, BMI, type of vaccination, vaccine interval in days, interval between second vaccination and antibody testing in days, rheumatic diagnosis, comorbidity and immunosuppressive therapy.

  • *Cogan-syndrome (n=2), peripheral spondyloarthritis (n=2), polychondritis (n=1), sarcoidosis (n=1).

  • AIRD, autoimmune rheumatic diseases; ANCA, antineutrophil cytoplasmic antibody; BMI, body mass index; RBD, receptor-binding domain; ref, reference; S/CO, signal/cut-off.